NexVas VI (Resverlogix Corp)

N/A

Report date: 2022/01/14 13:23:58

NME

Base Information

Drug NameNexVas VI (Resverlogix Corp)

Drug Alias NameNexVas Autoimmune (AI) programme - Resverlogixvascular pro-inflammatory mediator inhibitorsNexVas vascular inflammationZEN3317NexVas VI (vascular inflammation) therapy - Resverlogix +[14]

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionBromodomain-containing protein 4 inhibitors

TargetsBromodomain-containing protein 4

Therapy Area/IndicationsVascular Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesZenith Epigenetics Resverlogix Corp

China Registration ClassN/A

Develop Information

Active CompaniesZenith Epigenetics Resverlogix Corp

Inactive CompaniesN/A

Active IndicationsVascular Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A